Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Aspire Biopharma Holdings Inc's Competitiveness

Name: Aspire Biopharma Holdings Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Aspire Biopharma Holdings Inc (ASBP) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026

Competitors Tracked

Publicly traded peers

Peer Group Market Share

100.00 %

Share of combined sales, Q2 2026

Revenue Growth Y/Y

Q2 2026

Net Margin

-2,009.61 %

Q2 2026

Key Findings: Aspire Biopharma Holdings Inc vs Its Competitors

TTM: Trailing 12-month revenue of 0M vs -M combined for tracked competitors (100.0% combined share).
Trending: Latest-quarter revenue run-rate is accelerating (+145.9% annualized vs trailing 12 months).
Peer revenue share: Aspire Biopharma Holdings Inc accounted for 100.0% of combined revenue among its tracked peer group.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

ASBP Sales vs. its Competitors, Q2 2026

Aspire Biopharma Holdings Inc generated 100.00 % of the combined sales of its peer group.

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/ASBP/competitors                    

                        https://api.csimarket.com/api/v1/companies/ASBP/relationships                    

                        https://api.csimarket.com/api/v1/companies/ASBP/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Aspire Biopharma Holdings Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Aspire Biopharma Holdings Inc	No	-	-	No
High-Confidence Competitors (2)	-

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

ASBP Stock Performance relative to its Competitors

ASBP Competitors (weighted) Percent change over the selected range

Aspire Biopharma Holdings Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(0 of 2)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Aspire Biopharma Holdings Inc	-31.00 %	Underperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (2)	40.4%	63.2%
Similar-Size Competitors (0)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Aspire Biopharma Holdings Inc's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

ASBP Stock Performance relative to High-Confidence Competitors

ASBP High-Confidence Competitors (equal-weighted, 3) Percent change over the selected range

Aspire Biopharma Holdings Inc's Comment on Competition and Industry Peers

The company operates in the biopharmaceutical industry, which is characterized by rapid technological advancements and a focus on proprietary products. It competes with major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, government agencies, and public and private research organizations. Many competitors possess greater financial, technical, and human resources, along with more experience in product discovery, development, regulatory approvals, and commercialization. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Competition also occurs in recruiting qualified personnel, establishing clinical study sites, and acquiring complementary technologies. Additionally, smaller or early-stage companies can be significant competitors, particularly through collaborative efforts.

Aspire Biopharma Holdings Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
TZUP	Named by the company	85%	2022 to 2026	3
Datacentrex Inc	Named by the company	85%	2022 to 2026	3
Izea Worldwide Inc	Named by the company	85%	2022 to 2026	3
Instaprin	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Aspire Biopharma Holdings Inc's named competitors require a Commercial License.